1. Known pregnancy or lactation. 2. Estimated glomerular filtration rate (eGFR) 60 mL/min/1.73m2 or on dialysis (chronic renal disease stage 3-5). 3. History of active liver disease, cholelithiasis, hypothyroidism or rhabdomyolysis (suspected or confirmed). For purposes of the study, any history of chronic hepatopathy (including chronic hepatitis of any etiology, liver cirrhosis), recent history (last 12 months) of acute hepatitis of any etiology shall be considered as active liver disease , or in the context of COVID-19, increase in circulating AST or ALT >3 times the upper normal limit (to be performed on all patients at trial cost, unless already available in the patient within the last 72 hours). Fatty liver without hepatitis, or a remote history (>12 months) of acute viral (e.g., hepatitis A) or medication-induced hepatitis that has not progressed to chronic liver disease, do not constitute an exclusion criterion for the study. 4. Known hypersensitivity to fenofibrate or fenofibric acid. 5. Current treatment with fenofibrate, clofibrate, warfarin or other coumarinic anticoagulants, glimepiride, cyclosporine, tacrolimus. 6. Use of statins, except simvastatin or atorvastatin. For these 2 statins, patients taking doses >40 mg/day will be excluded. 8. Inability to read, write, or lack of access to a phone. 9. Patients with endotracheal intubation.

1. Known pregnancy or lactation. 2. Estimated glomerular filtration rate (eGFR) 60 mL/min/1.73m2 or on dialysis (chronic renal disease stage 3-5). 3. History of active liver disease, cholelithiasis, hypothyroidism or rhabdomyolysis (suspected or confirmed). For purposes of the study, any history of chronic hepatopathy (including chronic hepatitis of any etiology, liver cirrhosis), recent history (last 12 months) of acute hepatitis of any etiology shall be considered as active liver disease , or in the context of COVID-19, increase in circulating AST or ALT >3 times the upper normal limit (to be performed on all patients at trial cost, unless already available in the patient within the last 72 hours). Fatty liver without hepatitis, or a remote history (>12 months) of acute viral (e.g., hepatitis A) or medication-induced hepatitis that has not progressed to chronic liver disease, do not constitute an exclusion criterion for the study. 4. Known hypersensitivity to fenofibrate or fenofibric acid. 5. Current treatment with fenofibrate, clofibrate, warfarin or other coumarinic anticoagulants, glimepiride, cyclosporine, tacrolimus. 6. Use of statins, except simvastatin or atorvastatin. For these 2 statins, patients taking doses >40 mg/day will be excluded. 8. Inability to read, write, or lack of access to a phone. 9. Patients with endotracheal intubation.